Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
The CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...
Although the majority of claims involved COVID-19 medicines, most of the funds — $6.1 million — went to deaths and injuries caused by the H1N1 vaccine, such as Guillain-Barré syndrome.
Credit: Shutterstock / Mdisk Swedish biotechnology firm Hansa Biopharma has announced that its investigational drug imlifidase improved motor function in patients with Guillain-Barré Syndrome (GBS) in ...
The Background Rates of Adverse Events for Vaccine Evaluation in Africa project will look to understand the incidence rates of naturally occurring clinical events within African populations such as ...
The Wilkes-Barre General Hospital School of Nursing Alumni Association presented a donation to the Center for Nursing History of Northeastern Pennsylvania at Misericordia University on Oct. 22.